125 related articles for article (PubMed ID: 34185460)
1. CXCR4 as a prognostic marker in Egyptian chronic lymphocytic leukemia patients.
El-Sherif WT; Salah El-Din EM; Aly MM; Said MG; Nigm DA
Egypt J Immunol; 2021 Jul; 28(3):114-126. PubMed ID: 34185460
[TBL] [Abstract][Full Text] [Related]
2. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
Kashyap MK; Amaya-Chanaga CI; Kumar D; Simmons B; Huser N; Gu Y; Hallin M; Lindquist K; Yafawi R; Choi MY; Amine AA; Rassenti LZ; Zhang C; Liu SH; Smeal T; Fantin VR; Kipps TJ; Pernasetti F; Castro JE
J Hematol Oncol; 2017 May; 10(1):112. PubMed ID: 28526063
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1).
Möhle R; Failenschmid C; Bautz F; Kanz L
Leukemia; 1999 Dec; 13(12):1954-9. PubMed ID: 10602415
[TBL] [Abstract][Full Text] [Related]
4. CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease.
Barretina J; Juncà J; Llano A; Gutiérrez A; Flores A; Blanco J; Clotet B; Esté JA
Ann Hematol; 2003 Aug; 82(8):500-505. PubMed ID: 12783211
[TBL] [Abstract][Full Text] [Related]
5. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
6. CXCR4 overexpression in chronic lymphocytic leukemia associates with poorer prognosis: A prospective, single-center, observational study.
Xue X; Wen Z; Zhang X; Yang Y; Li Y; Liao R; Zheng Q; Fu Y; Liu Y; Liao H
Genes Immun; 2024 Apr; 25(2):117-123. PubMed ID: 38366101
[TBL] [Abstract][Full Text] [Related]
7. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.
Burger JA; Burger M; Kipps TJ
Blood; 1999 Dec; 94(11):3658-67. PubMed ID: 10572077
[TBL] [Abstract][Full Text] [Related]
8. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway.
Kashyap MK; Kumar D; Jones H; Amaya-Chanaga CI; Choi MY; Melo-Cardenas J; Ale-Ali A; Kuhne MR; Sabbatini P; Cohen LJ; Shelat SG; Rassenti LZ; Kipps TJ; Cardarelli PM; Castro JE
Oncotarget; 2016 Jan; 7(3):2809-22. PubMed ID: 26646452
[TBL] [Abstract][Full Text] [Related]
9. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma.
Ghobrial IM; Bone ND; Stenson MJ; Novak A; Hedin KE; Kay NE; Ansell SM
Mayo Clin Proc; 2004 Mar; 79(3):318-25. PubMed ID: 15008605
[TBL] [Abstract][Full Text] [Related]
10. Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia.
Butrym A; Gebura K; Iwaszko M; Kuliczkowski K; Bogunia-Kubik K; Mazur G
HLA; 2016 Jun; 87(6):432-8. PubMed ID: 27173875
[TBL] [Abstract][Full Text] [Related]
11. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
Burger M; Hartmann T; Krome M; Rawluk J; Tamamura H; Fujii N; Kipps TJ; Burger JA
Blood; 2005 Sep; 106(5):1824-30. PubMed ID: 15905192
[TBL] [Abstract][Full Text] [Related]
12. CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.
Majid A; Lin TT; Best G; Fishlock K; Hewamana S; Pratt G; Yallop D; Buggins AG; Wagner S; Kennedy BJ; Miall F; Hills R; Devereux S; Oscier DG; Dyer MJ; Fegan C; Pepper C
Leuk Res; 2011 Jun; 35(6):750-6. PubMed ID: 21093051
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of microRNA 17-92 cluster expression in Egyptian chronic lymphocytic leukemia patients.
Khalifa MM; Zaki NE; Nazier AA; Moussa MA; Haleem RA; Rabie MA; Mansour AR
J Egypt Natl Canc Inst; 2021 Dec; 33(1):37. PubMed ID: 34866170
[TBL] [Abstract][Full Text] [Related]
14. Global histone deacetylase enzymatic activity is an independent prognostic marker associated with a shorter overall survival in chronic lymphocytic leukemia patients.
Van Damme M; Crompot E; Meuleman N; Mineur P; Dessars B; El Housni H; Bron D; Lagneaux L; Stamatopoulos B
Epigenetics; 2014 Oct; 9(10):1374-81. PubMed ID: 25437053
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.
Pavlasova G; Borsky M; Seda V; Cerna K; Osickova J; Doubek M; Mayer J; Calogero R; Trbusek M; Pospisilova S; Davids MS; Kipps TJ; Brown JR; Mraz M
Blood; 2016 Sep; 128(12):1609-13. PubMed ID: 27480113
[TBL] [Abstract][Full Text] [Related]
16. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
Short NJ; Keating MJ; Wierda WG; Faderl S; Ferrajoli A; Estrov Z; Smith SC; O'Brien SM
Cancer; 2015 Nov; 121(21):3869-76. PubMed ID: 26218678
[TBL] [Abstract][Full Text] [Related]
18. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.
Burger JA; Tsukada N; Burger M; Zvaifler NJ; Dell'Aquila M; Kipps TJ
Blood; 2000 Oct; 96(8):2655-63. PubMed ID: 11023495
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum BDNF levels are associated with favorable outcome in CLL patients: Possible link to CXCR4 downregulation.
Azoulay D; Herishanu Y; Shapiro M; Brandshaft Y; Suriu C; Akria L; Braester A
Exp Hematol; 2018 Jul; 63():17-21.e1. PubMed ID: 29705266
[TBL] [Abstract][Full Text] [Related]
20. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Herishanu Y; Tadmor T; Braester A; Bairey O; Aviv A; Rahimi-Levene N; Fineman R; Levi I; Yuklea M; Ruchlemer R; Shvidel L; Polliack A
Hematol Oncol; 2019 Apr; 37(2):185-192. PubMed ID: 30756414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]